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Abstract
Hydroxychloroquine and chloroquine, also known as antimalarial drugs, are widely used in the treatment of
rheumatic diseases and have recently become the focus of attention because of the ongoing COVID-19 pandemic.
Rheumatologists have been using antimalarials to manage patients with chronic immune-mediated inflammatory
rheumatic diseases for decades. It is an appropriate time to review their immunomodulatory and anti-inflammatory
mechanisms impact on disease activity and survival of systemic lupus erythematosus patient, including antiplatelet
effect, metabolic and lipid benefits. We also discuss possible adverse effects, adding a practical and comprehensive
approach to monitoring rheumatic patients during treatment with these drugs.
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Background
Hydroxychloroquine (HCQ) and chloroquine (CQ),
known as antimalarial (AM) drugs, are widely used in
the treatment of rheumatic disorders, especially in
immune-mediated such as systemic lupus erythematosus
(SLE), cutaneous lupus [1–4] and rheumatoid arthritis
(RA) [5, 6]. Besides that, both the Brazilian Society of
Rheumatology (SBR) and the European League Against
Rheumatism (EULAR) recommend, in specific circum-
stances, the use of HCQ for primary Sjögren syndrome
(pSS) [7, 8] and antiphospholipid syndrome (APS) [9].
HCQ is currently preferred over chloroquine as it has a
better safety profile [10], especially regarding the risk of
retinopathy [11].
In this narrative review, the mechanism of action of
these medications, as well as their main clinical, bio-
logical and safety effects in patients with chronic
immune-mediated inflammatory rheumatic diseases
(CIMID) will be discussed. Therefore, studies of these
drugs related to COVID-19 will not be addressed in this
review.
Methods
The new scenario of COVID-19 pandemic brought
many medical challenges to physicians and health care
systems. In view of this situation, The Brazilian Society
of Rheumatology established a team of specialists from
its commissions to respond to the demands related to
the topic, especially those come from the Brazilian
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Ministry of Health. The discussion about the possible
use of AM in SARS-cov2 infection showed the oppor-
tunity to revisit the topic by rheumatologists. A writing
committee started gathering published research and ana-
lyzed it carefully. After discussion and debate, the com-
mittee members agreed on what would be the most
useful knowledge to be highlighted about AM for rheu-
matologists, and prepared this manuscript. In a time of
rapid response to a public health emergency, this type of
document needed to be produced quickly and was
evidence-informed, but not supported by complete evi-
dence reviews.
Pharmacological characteristics
CQ is a 4-aminoquinoline known since 1934, discovered
in the first half of the twentieth century as an effective
substitute for quinine. Currently, CQ is the drug of
choice for the treatment of malaria [12]. Hydroxychloro-
quine is a hydroxylated analogue of CQ that has both
antimalarial and antiinflammatory activities (Fig. 1).
These two molecules enter cells as non-protonated
forms and become protonated, inversely proportional to
pH, according to Henderson-Hasselbach’s law. There-
fore, these drugs are concentrated in acidic organelles,
including endosomes, lysosomes and Golgi vesicles, in-
creasing the pH [13].
Both drugs are weak bases and have a large volume of
distribution with a half-life of about 50 days. These drugs
interfere with lysosomal activity and autophagy, interact
with membrane stability and may alter signaling path-
ways and transcriptional activity, resulting in inhibition
of cytokine production and modulation of certain co-
stimulatory molecules. At the cellular level, they inhibit
the Toll-like receptors signaling and reduce the CD154
molecule expression in T cells. Effects on plasmacytoid
dendritic cells (pDCs), B cells and other antigen present-
ing cells have also been described [13].
HCQ is administered as a sulfate while chloroquine is
administered as a phosphate salt. The differences be-
tween the pharmacokinetic properties of CQ and HCQ
are presented in Table 1.
Mechanisms of action
The exact mechanism of action of HCQ and CQ in the
treatment of CIMID is not yet fully understood, but
there is strong evidence that they have an immunomod-
ulatory and antithrombotic effect [13, 14]. The proposed
mechanisms to explain these effects are (Fig. 2):
 Alkalinization of lysosomes and other intracellular
acid compartments with interference in
phagocytosis. The increase of intracellular pH causes
a selective change in the presentation of proper
antigens;
 Blockage of T-cell response and reduction of pro-
inflammatory cytokine production, including INF-γ,
TNF, IL-1 and IL-6;
 Blockage of Toll-like receptors 7 and 9, especially in
plasmacytoid dendritic cell with inhibition of INF-α,
which plays an important role in the pathophysi-
ology of SLE;
 cGAS-STING signaling inhibition;
 Inhibition of phospholipase A2 activity;
 Stimulation of nitric oxide production by endothelial
cells with antiproliferative effect;
 Antithrombotic effect through the inhibition of
platelet aggregation in a dose-dependent manner,
decreased production of arachidonic acid by acti-
vated platelets and action on antiphospholipid
antibodies.
 Action on glucose metabolism and lipid profile as a
non-immunomodulatory mechanism
Benefits in SLE
This class of medication has been used in the treat-
ment of SLE for more than 50 years. It is a chronic
autoimmune inflammatory disease that can affect sev-
eral organs and systems and has a variable incidence,
with 8.7 cases/100,000 inhabitants in Brazil [15]. It
mainly affects young women aged from 15 to 45
years-old with heterogeneous and pleomorphic clinical
manifestations [16, 17].
In 1976, Urowitz et al. described a bimodal mortality
pattern in lupus patients, with premature deaths related
to disease activity or infection, while late rate was more
associated with atherosclerotic disease [18]. Considering
the improvements in diagnosis and treatment, as well as
Fig. 1 Chemical structure of chloroquine (a) and
hydroxychloroquine (b)
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Table 1 Pharmacokinetic properties of chloroquine and hydroxychloroquine
Chloroquine Hydroxychloroquine
Oral absorption Upper gastrointestinal tract Upper gastrointestinal tract




Hepatic metabolism Desethylchloroquine 39% Desethylchloroquine 18%
Desethyl-hydroxychloroquine 16%
Renal clearance 51% 21%
Unmetabolized excretion 58% 62%
Terminal half-life 41 ± 11 days 45 ± 15 days
Adapted from: Schrezenmeier E et al. [13]
Fig. 2 Proposed mechanisms of action of antimalarials (chloroquine and hydroxychloroquine). APL: antiphospholipids; CQ: chloroquine; HCQ:
hydroxychloroquine; IL-1: interleukin 1; IL-6: interleukin-6; INF-α: interferon alpha; INF-γ: interferon gama; PLA-2: phospholipase A-2; TCR: T cell
receptor; TLR: toll like receptor; TNF: tumor necrose factor
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the reduction of complications related to disease itself or
its own treatment, the survival rate has increased in the
two last decades [19].
The treatment of SLE patients may be individualized
and targeted, according to the disease activity and sever-
ity. Additionally, patient education about the disease,
sun exposure protection, regular physical exercise, diet,
treatment of comorbidities (hypertension, diabetes, dys-
lipidemia, osteoporosis), avoiding smoking and perform-
ing adequate contraception and vaccines are important
approaches and should be stimulated for all patients.
The main goals of treatment in SLE are to increase
long-term survival, to induce and maintain remission, to
prevent damage and to improve quality of life [10].
CQ or preferably HCQ should be always recom-
mended for lupus patients, regardless other immunosup-
pressive medications and severity or type of clinical
manifestations, except if some contraindication or previ-
ous toxicity [10, 11]. Both of them promote multiple
benefits, including direct or indirect effects [20], such as
reducing disease activity and new flares [21]; improve-
ment of skin lesions and joint symptoms [22, 23]; pre-
vention of accrual damage [24, 25]; possible mortality
risk reduction [26, 27]; as well as some benefits on glu-
cose and lipid metabolism and reduction of thrombotic
phenomena [14].
Disease activity
AMs are widely used and recommended for the treat-
ment of SLE, since they promote an immunomodulatory
effect of the immune response and better control of dis-
ease activity [2].
Tsakonas et al. demonstrated 57%-risk reduction of
severe activity in quiescent lupus patients after HCQ,
suggesting some prevention benefit on disease activity
(RR = 0.43; 95% CI 0.17–1.12) [21]. The Canadian
Hydroxychloroquine Study Group randomized 47
lupus patients, who were with stable dose of HCQ, to
maintain on (n = 25) or to switch to placebo (n = 22).
After 6-month HCQ withdrawal, there was significant
2.5-increase of SLE activity (95% CI 1.08–5.58; p =
0.02). Interestingly, there was a non-significant higher
risk for severe activity, including vasculitis, transverse
myelitis and nephritis, in those that had stopped the
medication (RR = 6.1; 95% CI 0.72–52.54) [28]. Addi-
tionaly, some other studies have shown clinical wors-
ening after drug discontinuation [29].
Regarding lupus nephritis, Petri et al. have demon-
strated higher remission rate in 450 patients using HCQ
when compared to non-users after 1-year follow-up
(64% vs. 22%; p = 0.036) [30]. Also, the HCQ was a
stronger predictor of complete renal remission in lupus
patients when combined to mycophenolate than myco-
phenolate in monotherapy [31]. Thus, the SBR, the
ACR, and the EULAR consensus and recommendations
for treating lupus patients have recommended the HCQ
as an adjunctive treatment [1–4].
Damage accrual
Several studies have found relevant damage accrual in
SLE patients [24, 32–35]. Accordingly to the LUMINA
study, HCQ users had lower risk of developing new
damage in patients with less than 5 years of disease
(HR = 0.73; CI 95% 0.52–1.00; p = 0.05), especially in pa-
tients with no damage at baseline (HR = 0.55; CI 95%
0.34–0.87; p = 0.011) [24]. Another LUMINA analysis in
203 patients with lupus nephritis without renal damage
found that HCQ delayed the onset of kidney failure
(HR = 0.12; CI 95% 0.02–0.97; p = 0.046). The accumu-
lated kidney damage was higher in HCQ non-users in
class IV lupus nephritis [35]. Petri et al. evaluated 2054
patients and found that age, hypertension and use of
corticosteroids were main predictors of damage, while
HCQ had a protective effect (p = 0.06) [34].
Thrombotic events
HCQ reduces platelet aggregation and its antithrombotic
effect can be explained by the reduction of the formation
of antiphospholipid-β2-glycoprotein complexes on
monocytes surfaces [36] with protective effect in patients
with SLE [26, 37–40] (OR = 0.17; CI 95% 0.07–0.44; p <
0.0001) [38] and HR = 0.28; CI95% 0.08–0.90) [26]. Jung
et al. compared 54 patients with SLE and prior throm-
bosis with 108 lupus patients with no thrombosis and
demonstrated that AM were associated with lower risk
of thrombotic events, both arterial and venous (OR =
0.31; CI 95% 0.13–0.71) [41].
Glucose metabolism and lipid profile
In vitro and experimental models demonstrated that
HCQ improves insulin secretion and peripheral insulin
sensitivity [14]. Penn et al. found HCQ was associated
with lower fasting glycemia and Homeostatic Model As-
sessment (HOMA) index in patients with SLE [42].
Moreover, AM in monotherapy or associated with glu-
cocorticoids (GC) have also improved the lipid profile in
lupus patients because they provide hepatic cholesterol
synthesis reduction with inhibition of lysosomal func-
tion, as well as lysosomal cholesterol transport and me-
tabolism blockage. Other explanations are related to
lower LDL receptor activity and bile steroid precursors
and HMG-CoA reductase function gain [14]. Besides
that, chloroquine diphosphate increases low-density
lipoprotein removal from plasma in SLE patients [43].
Petri et al. found that HCQ was associated with lower
total cholesterol serum levels, regardless dosage (200 mg
or 400 mg/day), and it was able to mitigate the deleteri-
ous prednisone effect (10 mg/day) on total cholesterol
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[44]. Rahman et al. reported 4.1%-reduction of total
cholesterol serum levels after starting AM in 3 months
(p = 0.02). In 181 patients using GC and AM, the mean
total cholesterol was 11% lower than in 201 patients re-
ceiving comparable dosage of GC (p = 0.002) [45]. Cair-
oli et al. demonstrated a significant decrease in total
cholesterol (198 ± 33.7 vs. 183 ± 30.3 mg/dL; p = 0.023)
and LDL levels (117 ± 31.3 vs. 101 ± 26.2 mg/dL; p =
0.023) after the 3 months of HCQ therapy in SLE pa-
tients which determined a significant decrease in the fre-
quency of dyslipidemia (26% vs. 12.5%; p = 0.013) [46].
A recent systematic review and meta-analysis involving
data from nine studies and 823 participants has stated
that HCQ significantly reduced mean total cholesterol
plasmatic levels (26.8 mg/dL; 95% CI 8.3–45.3), as well
as mean LDL serum levels (24.3 mg/dL; CI95% 8.9–
39.8). However, it is important to note that other studies
had an extensive heterogeneity among them, including
lack of information about statin use [47]. Similarly, there
are controversial data regarding HDL status [14].
Survival
Ruiz-Irastorza et al. evaluated a cohort with 232 lupus
patients (64% on AMs). Among 23 patients who died,
19 (83%) had never received AMs. The cumulative
15-year survival rate was higher in those using AM
drugs (0.98 vs. 0.15; p < 0.001) [26]. Shinjo et al., ana-
lyzing 1480 patients from the GLADEL (Grupo Latino
Americano para Estudo do Lupus) found lower mor-
tality rate in AMs users for at least six consecutive
months (4.4% vs. 11.5%; p < 0.001). In addition, the
protective effect on mortality rate increased according
to longer exposition time to AMs [6 to 11 months:
3.85 (95%CI 1.41 to 8.37); 12 to 24 months: 2.7
(95%CI 1.41 to 4.76); and more than 24 months: 0.54
(95%CI 0.37 to 0.77)]. After adjustment to potential
confounders, AMs were associated with a 38% reduc-
tion in mortality (HR = 0.62; 95%CI 0.39–0.99) [27].
Pregnancy and lactation
The use of CQ and HCQ is not only allowed but is
recommended during pregnancy and lactation in SLE
patients [14]. A HCQ placebo-controlled study sug-
gested beneficial effect on disease activity [48] and
the interruption of HCQ was related to higher risk of
flares during pregnancy. In other words, AMs are rec-
ommended during the preconception period, preg-
nancy and lactation [49].
The presence of anti-Ro/SSA and anti-La/SSB anti-
bodies are associated with 1 to 2% risk of congenital
total atrioventricular block. When there is a maternal
history of an affected fetus or child, the recurrence rate
can increase 13 to 18%. HCQ is associated with lower
occurrence of neonatal cardiac lupus, especially if recur-
rent [50, 51].
More recently, a systematic review and meta-
analysis involving 6 studies and 870 pregnancies have
found no difference concerning prematurity and re-
stricted intrauterine growth in lupus patients exposed
(n = 308) or not exposed (n = 562) to HCQ. It is im-
portant to emphasize that these results should be ad-
dressed with caution due to huge heterogeneity
among the studies [52].
Benefits in RA
AMs are important as adjunctive therapy to treatment
with disease-modifying drugs (DMARDs) in RA, includ-
ing recommendations for treatment of SBR [5] and ACR
[6]. HCQ has been shown to improve clinical and la-
boratory findings in RA, particularly in early and mild
disease, although there was no protective effect on radio-
graphic progression [53]. Because of its good safety pro-
file, it currently being studied for the prevention of
future onset of rheumatoid arthritis (RA) in individuals
who have elevations of anti-cyclic citrullinated peptide
(anti-CCP3) antibodies [54].
Similarly to data from lupus patients, most of ef-
fects are also seen in RA, including improvement in
lipid profile and insulin resistance [55, 56]. In a mul-
ticenter study with 4905 RA patients, Wasko et al.
demonstrated that HCQ was associated with lower
risk of diabetes mellitus (HR = 0.62; 95% CI 0.42–
0.92) [56] and could be used for controlling trad-
itional cardiovascular risk factors [57].
Benefits in other immune-mediated diseases
Antimalarial drugs may be used to treat sarcoidosis, in-
cluding cutaneous sarcoidosis, pulmonary sarcoidosis,
neurosarcoidosis, and arthritis [58]. Although less effect-
ive than in patients with SLE, AM can be useful in for
cutaneous manifestations in dermatomyositis [59].
Safety
AMs are usually effective, safe, and well tolerated. Ac-
cording to the SBR, the Brazilian Society of Dermatology
and The Study Group on Inflammatory Bowel Diseases,
patients with CIMID on AMs are considered as non-
immunosuppressant medications [60]. There is no in-
creased risk of infections or even neoplasms in the
short- and long-term [61]. More frequently the adverse
events are related to gastrointestinal complaints, such as
abdominal pain, nausea, vomiting and diarrhea. To de-
crease these adverse effects, the HCQ can be taken once
or twice daily with a meal [62].
Patients with psoriasis, porphyria and alcoholism may
be more susceptible to adverse skin events, usually with-
out severity. In rare cases, hemolysis may occur in
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patients with glucose-6-phosphate dehydrogenase defi-
ciency [63]. Besides G6PD deficiency, the concomitant
use of HCQ with dapsone may enhance the risk of
hemolytic reactions [64].
There is no current recommendation to reduce the
dose of HCQ in patients with chronic kidney disease
[13]. Some experts recommend reducing the dose of
chloroquine phosphate by 50% if the glomerular filtra-
tion rate is less than 10 mL/minute, and in hemodialysis
or peritoneal dialysis patients [65]. Neither safety nor ef-
ficacy of HCQ has been established for chronic use in
children for juvenile idiopathic arthritis or for juvenile
SLE.
The main adverse events related to the use of AM are
summarized in Fig. 3.
Ocular toxicity
Both CQ and HCQ can cause ocular deposition, an ef-
fect more associated with CQ. Retinal changes are re-
lated to lysosomal degradation of the external
photoreceptor with lipofuscin accumulation in retinal
pigment epithelium [66].
Once symptomatic, the retinopathy associated with
AM is characterized by abnormalities of the retinal pig-
ment epithelium, which are detectable clinically, and
may later develop into the classic appearance of ‘bull’s
eye maculopathy’ with retinal pigment epithelial loss. At
this stage the visual loss is severe and irreversible and
may be complicated by secondary cystoid macular
oedema, epiretinal membrane and other sequalae [67].
Although rare, the retinopathy is one of main adverse
events related to AMs [14]. Considering the recom-
mended dosages, the 5-year, 10-year and 20-year toxicity
risk is lesser than 1%, below 2 and 20%, respectively.
After 20 years of use, the risk increases 4% each year for
those no previous toxicity [11].
More recently, the hydroxychloroquinemia has been
reported as a risk factor for retinopathy in 537 lupus pa-
tients (total prevalence = 4.3%) [68]. Other risk factors
associated with retinopathy were age, duration of use
and high body mass index (BMI).
In 2016, the American Society of Ophthalmology up-
dated its recommendations for retinopathy screening in
CQ or HCQ users. According to them, the maximum
daily dosage of HCQ should be ≤5 mg/kg. The main risk
factors for ocular toxicity are daily dose above the rec-
ommended, duration of use, renal failure, previous
maculopathy or retinopathy and concomitant use of
tamoxifen. Other risk factors include advanced age, liver
failure and genetic factors related to abnormalities of the
ABCA4 gene or cytochrome P450. It is recommended
that patients initiating the drug undergo eye examination
within the first year of treatment. Although visual field
examination and spectral-domain optical coherence
tomography (SD OCT) are very useful, they are not
mandatory at the beginning of treatment, unless the
Fig. 3 Main adverse events related to the use of antimalarials
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patient has risk factors or other diseases that may affect
the initial screening tests. In the absence of major risk
factors, screening tests may be performed annually after
5 years of baseline assessment. If risk factors are present,
screening tests should be performed annually or at
shorter intervals soon after beginning AMs, and auto-
mated visual field assessment and OCT-SD are recom-
mended. Additional tests in some situations may be
indicated, such as the multifocal electroretinogram
(mfERG), which provides objective information of visual
field, especially in Asian patients [11].
Adverse dermatologic events
The use of antimalarials may provoke adverse dermato-
logic effects of varying severity, being drug eruptions or
rashes the most common [69]. Both CQ and HCQ
bound to melanin and can deposit on the skin, with the
possibility of cutaneous hyperpigmentation (grayish
color) in long-term, especially with CQ [66].
A study that compared acitretin with HCQ for the
treatment of cutaneous lupus found around 27% of pa-
tients with dry skin complaints; itching and burning sen-
sation on the skin in 17%; dermatitis in 3% and
desquamation in 3% of those using HCQ [70]. Also,
grayish pigmentation of the skin and oral mucosa has
been associated with longer use, higher levels of hydro-
xychloroquinemia, as well as the use of acetyl salicylic
acid and oral anticoagulants, sometimes with reports of
microtrauma and local ecchymosis preceding hyperpig-
mentation [71, 72]. Cases of worsening psoriasis are also
described with the use of medication [73]. Acute gener-
alized exanthematous pustulosis is rare and described in
1/5,000,000 inhabitants [74].
A recent systematic review including ninety-four ar-
ticles, comprising a total of 689 adverse dermatologic
side effects, has shown that drug eruption or rash
(358 cases) were the most frequent, followed by cuta-
neous hyperpigmentation (116 cases), pruritis (62
cases), acute generalized exanthematous pustulosis
(27cases), Stevens-Johnson syndrome or toxic epider-
mal necrolysis (26 cases), hair loss (12 cases), and
stomatitis (11 cases) [69].
Cardiotoxicity
Although rare, it can be a serious adverse event [75].
Both cardiomyopathy and conduction disorders (for ex-
ample, QT prolongation) are described. A possible
mechanism involves a lysosomal pathway dysfunction
with metabolite products (glycogen and phospholipids)
intracellular accumulation [76].
A systematic review about CQ and HCQ cardiotoxicity
found 86 articles, comprising only 127 patients in case
reports or small case series, most of them were SLE (n =
49) or RA patients (n = 28). Most patients (58.3%) were
treated with CQ with a median time of use of 7 years (3
days to 35 years) and median cumulative dose of 803 g
(1235 g for HCQ). Heart rhythm problems were the
main reported side effects, affecting 85% of patients.
Other non-specific cardiac events included ventricular
hypertrophy, hypokinesia, valve dysfunction and pul-
monary arterial hypertension. It is worth mentioning
that 38 cases were classified as probably related to ad-
verse drug events, 69 as possibly associated and in 20
cases it was not possible to indicate this association. It
was not possible to classify this association as definitive
for any case, using the Naranjo Scale. The authors could
not definitively exclude the possibility that some cardiac
complications were due to the disease itself or to differ-
ential diagnoses (Fabry disease, for example). Determin-
ation of the risk for cardiac complications attributed to
the medications was not possible because of the lack of
randomized controlled trials [75].
Other studies suggest that older age, duration of medi-
cation use, dosage above that recommended by weight,
use of CQ instead of HCQ, pre-existing heart disease
and renal failure may be risk factors for medication car-
diotoxicity. In addition, the risk may be greater in those
who use other medications that also lead to prolongation
of the QT interval or that increase the serum level of
QC [77–79]. A study suggested that SLE patients using
AM drugs with persistently elevated creatine phosphoki-
nase (CPK) should be monitored periodically and spe-
cific biomarkers, such as troponin and brain natriuretic
peptide (BNP), may be useful as a screening tool for car-
diotoxicity diagnosis by AMs. The electrocardiogram,
echocardiogram and magnetic resonance imaging can
provide more information in suspicious cases, as well as
endomyocardial biopsy, if necessary [80]. At the mo-
ment, there are no consensus and guidelines which are
the best methods and interval to monitor cardiotoxicity
with chronic use of AM.
On the other hand, it is important to highlight HCQ
and CQ have a protective effect on cardiovascular risk,
anti-thrombotic mechanisms and on survival rate in
lupus patients.
Myotoxicity
It has been described in a few cases, especially associated
to CQ. Patients with myopathy have proximal muscle
weakness without myalgia or muscle enzymes changes
(or slightly elevated more rarely). Patients can improve
with medication discontinuation [63].
Neurotoxicity
Central nervous system toxicity includes headache, dizzi-
ness, vertigo and tinnitus. There are rare case reports of
seizures related to reduction of seizure threshold and
psychosis, especially when combined to GC.
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Neuromyopathy and peripheral polyneuropathy are also
rare, occurring in patients with worsening renal function
and using CQ [62, 63].
Drug interactions
HCQ and CQ are substrates for cytochrome P450 en-
zymes, responsible for the metabolism of multiple
drugs. Cytochrome P450 enzymes dealkylate AMs to
their active metabolites. Thus, the concomitant use of
AMs can lead to increased levels of digoxin, cyclo-
sporine and metoprolol [62]. HCQ can reduce gastro-
intestinal absorption of methotrexate, since it alters
the local pH and it can explain lower toxicity of
methotrexate when combined. Antacids may decrease
oral bioavailability of CQ [13].
Special attention should be given to other concomitant
drugs, such as macrolides, quinolones, some antivirals
and antipsychotics, because they can also lead to QT
interval enlargement (Fig. 4) [13, 81].
Recommendations
Since this is a narrative review, it is not possible to make
formal recommendations, but suggestions for monitor-
ing and proposal of key messages are valuable, and pro-
vide information about AM use for health-care
providers, especially rheumatologists. These key mes-
sages are depicted in Table 2.
Conclusions
Given its multiple benefits, the use of AMs, prefera-
bly HCQ, should be encouraged to SLE patients, un-
less there is any contraindication. In other diseases
like RA, pSS, APS, dermatomyositis and sarcoidosis
some studies also show positive data, especially
under specific circumstances. The majority of the
side effects occur after a wide range of cumulative
dosages.
It is a low-cost and widely available medication,
whose safety profile is well known and acceptable. In
addition, considering its pharmacokinetic properties
(long half-life), it is possible to measure its serum
concentration as a marker of treatment adherence
and potential long-term toxicity, when necessary and
available.
Fig. 4 Main drug interactions with antimalarials related to QT interval enlargement. Adapted from: Li et al., 2010 [78]
Table 2 Key messages regarding safety of treatment with
antimalarial drugs
- Daily dose not greater than 5 mg/Kg
- Regular screening for retinal toxicity according to risk factors
- Monitoring of complete blood count at the beginning and during
prolonged therapy
- Physical examination with attention to muscle strength and reflexes
- Monitoring of QT interval prolongation in at-risk patients
- Caution in hepatic and renal impairment, use of other medications
that lead to prolongation of the QT interval or that increase the serum
level of antimalarials, alcoholism, concurrent antidiabetic agents,
porphyria, psoriasis.
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